These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33004339)

  • 1. TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
    Cocco E; Lee JE; Kannan S; Schram AM; Won HH; Shifman S; Kulick A; Baldino L; Toska E; Arruabarrena-Aristorena A; Kittane S; Wu F; Cai Y; Arena S; Mussolin B; Kannan R; Vasan N; Gorelick AN; Berger MF; Novoplansky O; Jagadeeshan S; Liao Y; Rix U; Misale S; Taylor BS; Bardelli A; Hechtman JF; Hyman DM; Elkabets M; de Stanchina E; Verma CS; Ventura A; Drilon A; Scaltriti M
    Cancer Discov; 2021 Jan; 11(1):126-141. PubMed ID: 33004339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.
    Wang J; Zhou Y; Tang X; Yu X; Wang Y; Chan S; Song X; Tu Z; Zhang Z; Lu X; Zhang Z; Ding K
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
    Drilon A; Nagasubramanian R; Blake JF; Ku N; Tuch BB; Ebata K; Smith S; Lauriault V; Kolakowski GR; Brandhuber BJ; Larsen PD; Bouhana KS; Winski SL; Hamor R; Wu WI; Parker A; Morales TH; Sullivan FX; DeWolf WE; Wollenberg LA; Gordon PR; Douglas-Lindsay DN; Scaltriti M; Benayed R; Raj S; Hanusch B; Schram AM; Jonsson P; Berger MF; Hechtman JF; Taylor BS; Andrews S; Rothenberg SM; Hyman DM
    Cancer Discov; 2017 Sep; 7(9):963-972. PubMed ID: 28578312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
    Roa P; Foglizzo V; Harada G; Repetto M; Kulick A; de Stanchina E; de Marchena M; Auwardt S; Sayed Ahmed S; Bremer NV; Yang SR; Feng Y; Zhou C; Kong N; Liang R; Xu H; Zhang B; Bardelli A; Toska E; Ventura A; Drilon A; Cocco E
    Br J Cancer; 2024 Aug; 131(3):601-610. PubMed ID: 38902532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy.
    Xiang S; Wang J; Huang H; Wang Z; Song X; Zhou Y; Jin F; He X; Zhang ZM; Tu Z; Ding K; Zhang Z; Lu X
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114899. PubMed ID: 36410169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib.
    Xiang S; Lu X
    Acta Pharm Sin B; 2024 Feb; 14(2):517-532. PubMed ID: 38322338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.
    Wang Z; Wang J; Wang Y; Xiang S; Song X; Tu Z; Zhou Y; Zhang ZM; Zhang Z; Ding K; Lu X
    J Med Chem; 2022 Apr; 65(8):6325-6337. PubMed ID: 35426680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation.
    Zhuo LS; Wang MS; Wu FX; Xu HC; Gong Y; Yu ZC; Tian YG; Pang C; Hao GF; Huang W; Yang GF
    J Med Chem; 2021 Oct; 64(20):15503-15514. PubMed ID: 34668694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.
    Wang Z; Wang J; Wang Y; Xiang S; Zhou H; Song S; Song X; Tu Z; Zhou Y; Ding K; Zhang ZM; Zhang Z; Lu X
    J Med Chem; 2023 Sep; 66(18):12950-12965. PubMed ID: 37676745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance.
    Qin Q; Guo Z; Lu S; Wang X; Fu Q; Wu T; Sun Y; Liu N; Zhang H; Zhao D; Cheng M
    Eur J Med Chem; 2024 Jan; 264():115953. PubMed ID: 38029466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
    Somwar R; Hofmann NE; Smith B; Odintsov I; Vojnic M; Linkov I; Tam A; Khodos I; Mattar MS; de Stanchina E; Flynn D; Ladanyi M; Drilon A; Shinde U; Davare MA
    Commun Biol; 2020 Dec; 3(1):776. PubMed ID: 33328556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance.
    Gong Y; Wu FX; Wang MS; Xu HC; Zhuo LS; Yang GF; Huang W
    Eur J Med Chem; 2022 Nov; 241():114654. PubMed ID: 35961071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
    Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
    Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
    Drilon A; Ou SI; Cho BC; Kim DW; Lee J; Lin JJ; Zhu VW; Ahn MJ; Camidge DR; Nguyen J; Zhai D; Deng W; Huang Z; Rogers E; Liu J; Whitten J; Lim JK; Stopatschinskaja S; Hyman DM; Doebele RC; Cui JJ; Shaw AT
    Cancer Discov; 2018 Oct; 8(10):1227-1236. PubMed ID: 30093503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
    Murray BW; Rogers E; Zhai D; Deng W; Chen X; Sprengeler PA; Zhang X; Graber A; Reich SH; Stopatschinskaja S; Solomon B; Besse B; Drilon A
    Mol Cancer Ther; 2021 Dec; 20(12):2446-2456. PubMed ID: 34625502
    [No Abstract]   [Full Text] [Related]  

  • 17. Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
    Cocco E; Schram AM; Kulick A; Misale S; Won HH; Yaeger R; Razavi P; Ptashkin R; Hechtman JF; Toska E; Cownie J; Somwar R; Shifman S; Mattar M; Selçuklu SD; Samoila A; Guzman S; Tuch BB; Ebata K; de Stanchina E; Nagy RJ; Lanman RB; Houck-Loomis B; Patel JA; Berger MF; Ladanyi M; Hyman DM; Drilon A; Scaltriti M
    Nat Med; 2019 Sep; 25(9):1422-1427. PubMed ID: 31406350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTRK fusion-positive cancers and TRK inhibitor therapy.
    Cocco E; Scaltriti M; Drilon A
    Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.
    Tanaka H; Sase H; Tsukaguchi T; Hasegawa M; Tanimura H; Yoshida M; Sakata K; Fujii T; Tachibana Y; Takanashi K; Higashida A; Hasegawa K; Ono Y; Oikawa N; Mio T
    Mol Cancer Ther; 2018 Dec; 17(12):2519-2529. PubMed ID: 30242093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.
    Harada G; Drilon A
    Cancer Genet; 2022 Jun; 264-265():33-39. PubMed ID: 35334340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.